Centatin

Drug Profile

Centatin

Alternative Names: 80-574; 80/574; CDRI 80/574; CDRI 80574

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Central Drug Research Institute
  • Developer Central Drug Research Institute; Zydus Cadila
  • Class Antihyperlipidaemics; Pregnadienes
  • Mechanism of Action Farnesoid X activated receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipidaemia

Most Recent Events

  • 25 Aug 2015 Phase-III development for Hyperlipidaemia (Combination therapy) is ongoing in India
  • 11 Aug 2010 The programme is still in active development
  • 29 Oct 2009 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top